About: Non-small cell lung cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Non-small cell lung cancer - genetic predictors Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer that is the leading cause of cancer-related mortality worldwide. Several predictive markers have been found in NSCLC patients to date but only a few are currently used for tailored therapy. METHODS AND RESULTS: PubMed and Web of Science online databases were used to search review and original articles on the most important predictive markers in NSCLC. CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). Other markers, such as KRAS mutation, EGFR T790M mutation and C-MET amplification, are responsible for resistance to these inhibitors. Overcoming of this resistance as well as discovery of new potential markers and inhibitors is the main goal of ongoing research and clinical trials in NSCLC. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer that is the leading cause of cancer-related mortality worldwide. Several predictive markers have been found in NSCLC patients to date but only a few are currently used for tailored therapy. METHODS AND RESULTS: PubMed and Web of Science online databases were used to search review and original articles on the most important predictive markers in NSCLC. CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). Other markers, such as KRAS mutation, EGFR T790M mutation and C-MET amplification, are responsible for resistance to these inhibitors. Overcoming of this resistance as well as discovery of new potential markers and inhibitors is the main goal of ongoing research and clinical trials in NSCLC. (en)
Title	Non-small cell lung cancer - genetic predictors Non-small cell lung cancer - genetic predictors (en)
skos:prefLabel	Non-small cell lung cancer - genetic predictors Non-small cell lung cancer - genetic predictors (en)
skos:notation	RIV/61989592:15110/13:33143716!RIV14-MZ0-15110___
http://linked.open...avai/riv/aktivita	P S
http://linked.open...avai/riv/aktivity	P(ED0030/01/01), P(GD303/09/H048), P(NT13569), S
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Drábek, Jiří Hajdúch, Marián Trojanec, Radek Koudeláková, Vladimíra Kneblová, Magdalena
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	92005
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/13:33143716
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	resistance; tyrosine kinase inhibitors; ROS1; C-MET; ALK; KRAS; EGFR; NSCLC (en)
http://linked.open.../riv/klicoveSlovo	EGFR KRAS tyrosine kinase inhibitors ALK resistance NSCLC C-MET ROS1
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[8D971AB4D0F4]
http://linked.open...i/riv/nazevZdroje	Biomedical Papers-Olomouc
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	5 (xsd:int)
http://linked.open...cetTvurcuVysledku	5 (xsd:int)
http://linked.open...vavai/riv/projekt	Identification of prognostic and predictive factors in non-small cell lung cancer patients treated by adjuvant chemotherapy. Biomedicine for regional development and human resources Molecular mechanisms of selected pathological processes in the cell
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	157
http://linked.open...iv/tvurceVysledku	Drábek, Jiří Hajdúch, Marián Trojanec, Radek Kneblová, Magdalena Koudeláková, Vladimíra
issn	1213-8118
number of pages	12 (xsd:int)
http://bibframe.org/vocab/doi	10.5507/bp.2013.034
http://localhost/t...ganizacniJednotka	15110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software